ClinicalTrials.gg
TerminatedNCT02119650Updated Feb 13, 2018Results posted

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

A Phase 2 interventional study of Ruxolitinib and Placebo in NSCLC (Non-small Cell Lung Carcinoma), sponsored by Incyte Corporation. Terminated at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Incyte Corporation.

Enrollment
10th of 30
76 · median 53
Started
2014
with 2 others
Phase 2
9 of 30
none open now
Registered
1st of 30
by date

Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Read the detailed description

The study consisted of an open-label, safety run-in (consisting of 1 to 4 cohorts of 9 participants each), to confirm the safety of ruxolitinib in combination with pemetrexed/cisplatin in participants with nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent. Participants in the safety run-in received open-label ruxolitinib and pemetrexed and cisplatin.

In the second part of the study, participants enrolled and randomized and received pemetrexed and cisplatin (open-label) and either ruxolitinib or placebo in a blinded manner. The dose of ruxolitinib administered was determined from the data produced in the safety run-in phase.

Treatment consisted of repeating 21-day cycles. Participants received infusions of pemetrexed and cisplatin on Day 1 of each cycle and ruxolitinib/placebo was self-administered during the entire cycle. Maintenance therapy with ruxolitinib or placebo in combination with pemetrexed, based on the original treatment assignment, was allowed for participants eligible for maintenance therapy.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Carcinoma)

Keywords

  • Non small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without or neoadjuvant chemotherapy).
  • Radiographically measurable or evaluable disease.
  • of at least 12 weeks.
  • Tumor without activating driver mutations for which there is available therapy (eg, tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).
  • An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

    • Criteria:

      • C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1
      • C-reactive protein >10 mg L AND albumin \<35 g/L; Score = 2
  • (ECOG) performance status of 0 to 1.
  • Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Squamous or mixed histology (eg, adenosquamous) NSCLC
  • Previous systemic therapy for advanced or disease.
  • Known active central nervous system (CNS) metastases.
  • Current or previous other within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
  • Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including functional classification of 3, or arrhythmia requiring treatment.
  • Uncontrolled concomitant medical conditions, including, but not limited to, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric diseases.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Ruxolitinib plus Pemetrexed/Cisplatin

    Drug: Ruxolitinib · Drug: Pemetrexed · Drug: Cisplatin

  • Active comparator
    Placebo plus Pemetrexed/Cisplatin

    Drug: Placebo · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • 5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))

    Also known as: Jakafi ®, Jakavi ®

  • DrugPlacebo

    5 mg matching placebo tablets to be administered by mouth

  • 500 mg/m\^2 administered as an intravenous infusion over 10 minutes

    Also known as: Alimta®

  • 75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis were censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.

    Time frame: Randomization until death due to any cause; up to 16 months or data cutoff 11FEB2016.

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum Longest Diameter (LD) recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions or increase in disease burden for subjects with only nonmeasurable disease.

    Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 16 months or to the data cutoff 11FEB2016.

  2. Objective Response Rate (ORR)

    Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

    Time frame: Baseline through end of study; up to 16 months or to the data cutoff 11FEB2016.

  3. Duration of Response

    For objective responders, the duration of response is defined as the difference of the end of response and the start of response. The start of a response was the first visit where the subject achieves PR or better based on RECIST v1.1 criteria. The end of response was the first visit after PD based on RECIST v1.1 criteria.

    Time frame: From the start of response to the end of response; up to 16 months or to the data cutoff 11FEB2016.

  4. Participants With Treatment-emergent Adverse Events (TEAEs)

    A treatment-emergent AE was defined as an event occurring (or worsening of any pre-existing) after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

    Time frame: Baseline through approximately 30 days post treatment discontinuation; up to 16 months or to the data cutoff 11FEB2016.

07

Results

Posted Jun 14, 2017
Limitations and caveats
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

Participant flow

This study was conducted at 42 study centers (25 in the United States, 4 in Spain, 3 in France, 3 in Portugal, 2 in Denmark, 2 in Germany, 2 in Italy, 1 in the Netherlands).

Participant flow — Overall Study
MilestoneDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Started3937
Completed1411
Not completed2526
Withdrew: Adverse event34
Withdrew: Subject decision23
Withdrew: Disease progression1114
Withdrew: Death51
Withdrew: Noncompliance with study treatment11
Withdrew: Study terminated by the sponsor10
Withdrew: Physician decision02
Withdrew: Multiple reasons for termination21

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis were censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.

Time frame:
Randomization until death due to any cause; up to 16 months or data cutoff 11FEB2016.
Reported as:
Median · months
Overall Survival (OS)
monthsDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Overall Survival (OS)7.5 (5.7 to NA)5.9 (4.0 to NA)
Statistical analysis
  • Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin vs Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin · Log Rank · p = 0.7562 · Hazard ratio (hr): 0.877 · 80% CI 0.509 to 1.51The 2-sided p-value was calculated based on the log-rank test and stratified by modified Glasgow Prognostic Score (mGPS).
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum Longest Diameter (LD) recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions or increase in disease burden for subjects with only nonmeasurable disease.

Time frame:
Randomization to disease progression, or death due to any cause if sooner; up to 16 months or to the data cutoff 11FEB2016.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryObjective Response Rate (ORR)

Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

Time frame:
Baseline through end of study; up to 16 months or to the data cutoff 11FEB2016.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Overall Response1213
Complete Response00
Partial Response1213
Stable Disease45
Progressive Disease64
Unable to Evaluate23
Not Assessed1512
SecondaryDuration of Response

For objective responders, the duration of response is defined as the difference of the end of response and the start of response. The start of a response was the first visit where the subject achieves PR or better based on RECIST v1.1 criteria. The end of response was the first visit after PD based on RECIST v1.1 criteria.

Time frame:
From the start of response to the end of response; up to 16 months or to the data cutoff 11FEB2016.
Reported as:
Median · weeks
Duration of Response
weeksDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Duration of Response20.14 (18.00 to 30.71)12.14 (6.00 to 24.00)
SecondaryParticipants With Treatment-emergent Adverse Events (TEAEs)

A treatment-emergent AE was defined as an event occurring (or worsening of any pre-existing) after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

Time frame:
Baseline through approximately 30 days post treatment discontinuation; up to 16 months or to the data cutoff 11FEB2016.
Reported as:
Count of participants · Participants
Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
Participants who had any TEAEs3936
Participants who had treatment-related TEAEs1628
Participants with any serious TEAE1916
Participants who had Grade 3 or higher TEAEs2522
Participants with a fatal TEAE44
TEAEs related to reference therapy3035
Participants who were hospitalized due to TEAEs1615
Participants who discontinued drug due to TEAEs24
Participants who interrupted drug due to TEAEs1115
Discontinued reference therapy due to TEAEs47
Interrupted reference therapy due to TEAEs87
Participants given concomitant meds due to TEAEs3632
Procedure/nondrug therapy due to TEAEs1712

Adverse events

Collected over From the first dose of study medication through approximately 30 days post treatment discontinuation; up to 16 months or to the data cutoff 11FEB2016.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Treatment: Ruxolitinib + Pemetrexed/Cisplatin—19/39 (48.7%)37/39 (94.9%)
Double-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin—16/37 (43.2%)36/37 (97.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
PneumoniaInfections and infestations3/393/37
AnemiaBlood and lymphatic system disorders3/391/37
DyspnoeaRespiratory, thoracic and mediastinal disorders3/392/37
ConstipationGastrointestinal disorders0/392/37
Atrial fibrillationCardiac disorders0/392/37
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/392/37
General physical health deteriorationGeneral disorders0/392/37
Pleuritic painRespiratory, thoracic and mediastinal disorders0/392/37
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/390/37
VomitingGastrointestinal disorders2/390/37
Most frequent other events
Showing 10 of 70
Most frequent other events
EventDouble-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/Cisplatin
NauseaGastrointestinal disorders20/3932/37
AnaemiaBlood and lymphatic system disorders15/3912/37
FatigueGeneral disorders13/3914/37
Decreased appetiteMetabolism and nutrition disorders5/3914/37
ConstipationGastrointestinal disorders13/3913/37
VomitingGastrointestinal disorders7/3912/37
AstheniaGeneral disorders7/3912/37
DiarrhoeaGastrointestinal disorders9/3910/37
StomatitisGastrointestinal disorders10/397/37
CoughRespiratory, thoracic and mediastinal disorders6/399/37

Baseline characteristics

The intent-to-treat (ITT) population consisted of participants that were randomized in the study.

Age, Continuous
Age, Continuous(years)Double-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/CisplatinTotal
Mean61.6 ± 8.8562.0 ± 8.5561.8 ± 8.65
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/CisplatinTotal
Female151429
Male242347
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/CisplatinTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American202
White363369
More than one race000
Unknown or Not Reported123
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Double-Blind Treatment: Ruxolitinib + Pemetrexed/CisplatinDouble-Blind Treatment: Placebo Plus Pemetrexed/CisplatinTotal
Mean27.67 ± 6.40227.65 ± 7.2627.66 ± 6.787
08

Study locations

30 sites
  • Phoenix, Arizona, United States
  • Fayetteville, Arkansas, United States
  • Fresno, California, United States
  • La Jolla, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Lone Tree, Colorado, United States
  • Norwich, Connecticut, United States
  • Southington, Connecticut, United States
  • Augusta, Georgia, United States
  • Joliet, Illinois, United States
  • Indianapolis, Indiana, United States
  • Lafayette, Indiana, United States
  • Kansas City, Kansas, United States
  • Detroit, Michigan, United States
  • Saint Louis, Missouri, United States
  • Reno, Nevada, United States
  • Lebanon, New Hampshire, United States
  • Mount Kisco, New York, United States
  • New York, New York, United States
  • Winston-Salem, North Carolina, United States
  • Canton, Ohio, United States
  • Portland, Oregon, United States
  • Chattanooga, Tennessee, United States
  • Knoxville, Tennessee, United States
  • Memphis, Tennessee, United States
  • Ogden, Utah, United States
  • Leesburg, Virginia, United States
  • Kennewick, Washington, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Feb 2016, 24 months.

Results were first posted in Jun 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2014
First posted
Apr 22, 2014
StartActual
Feb 11, 2014
Primary completionActual
Feb 11, 2016
CompletionActual
Jun 21, 2016
Results first posted
Jun 14, 2017
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02119650
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 22, 2014
Start date
Feb 11, 2014
Primary completion
Feb 11, 2016
Completion
Jun 21, 2016
Results posted
Jun 14, 2017
Last update
Feb 13, 2018

Study contacts

Gerard T Kennealey, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion